- id: rule_oncology_gcsf_prophylaxis
  name: G-CSF Prophylaxis for Neutropenia
  description: Prior authorization for granulocyte colony-stimulating factor prophylaxis during chemotherapy
  type: PRIOR_AUTH
  scope:
    service_types: ["MEDICAL"]
    place_of_service: ["11", "22", "19", "99"]
  conditions:
    all_of:
      - service_code:
          any_of:
          - J1442  # Injection, filgrastim (G-CSF)
          - J1447  # Injection, tbo-filgrastim
          - J2505  # Injection, pegfilgrastim
          - '96372' # Subcutaneous injection
      - diagnosis_code:
          any_of:
          - C78.00  # Secondary malignant neoplasm
          - C80.1   # Malignant neoplasm, unspecified
          - C50.911 # Breast cancer
          - C34.10  # Lung cancer
          - C18.9   # Colorectal cancer
          - Z51.11  # Encounter for antineoplastic chemotherapy
      - prior_service_within_days:
          service_codes:
          - '96413' # Recent chemotherapy administration
          - '96415'
          - '96416'
          days: 7
          description: Chemotherapy administration within past week
      - any_of:
        - all_of:
          - patient_age:
              min: 65
          - prior_service_within_days:
              service_codes:
              - '96413' # Intensive chemotherapy regimen
              days: 14
              description: Intensive chemotherapy in elderly patient within past 2 weeks
        - all_of:
          - prior_service_within_days:
              service_codes:
              - '85025' # ANC <1000 cells/μL
              days: 7
              description: Neutropenia documented within past week
        - all_of:
          - prior_service_within_days:
              service_codes:
              - '99221' # Previous febrile neutropenia hospitalization
              - '99222'
              - '99223'
              days: 90
              description: History of febrile neutropenia within past 90 days
      - prior_service_within_days:
          service_codes:
          - '99213' # Oncology evaluation
          - '99214'
          - '99215'
          days: 14
          description: Oncology evaluation within past 2 weeks
      - none_of:
        - diagnosis_code:
            any_of:
            - C95.90 # Acute leukemia (different G-CSF protocols)
            - C81.90 # Lymphoma (hematology-oncology management)
  logic:
    outcome: approved
    reason: G-CSF prophylaxis approved for appropriate neutropenia risk with oncology oversight
  metadata:
    source: UnitedHealth Medical Policy 2025.09
    effective_date: '2025-09-01'
    clinical_rationale: G-CSF reduces infection risk in patients at high risk for febrile neutropenia

- id: rule_oncology_erythropoietin_cancer
  name: Erythropoietin for Cancer-Related Anemia
  description: Prior authorization for erythropoiesis-stimulating agents in cancer patients
  type: PRIOR_AUTH
  scope:
    service_types: ["MEDICAL"]
    place_of_service: ["11", "22", "19"]
  conditions:
    all_of:
      - service_code:
          any_of:
          - J0881  # Injection, darbepoetin alfa
          - J0885  # Injection, epoetin alfa
          - '96365' # IV infusion
      - diagnosis_code:
          any_of:
          - C78.00  # Secondary malignant neoplasm
          - C80.1   # Malignant neoplasm, unspecified
          - Z51.11  # Encounter for antineoplastic chemotherapy
          - D63.0   # Anemia in neoplastic disease
      - prior_service_within_days:
          service_codes:
          - '85025' # Hemoglobin <10 g/dL
          - '85027'
          days: 14
          description: Hemoglobin <10 g/dL within past 2 weeks
      - prior_service_within_days:
          service_codes:
          - '96413' # Palliative chemotherapy only
          - '96415'
          days: 30
          description: Palliative chemotherapy within past 30 days
      - prior_service_within_days:
          service_codes:
          - '82728' # Iron studies normal
          - '82607' # B12 level normal
          - '82746' # Folate level normal
          days: 60
          description: Nutritional deficiencies excluded within past 60 days
      - none_of:
        - prior_service_within_days:
            service_codes:
            - '96413' # Curative-intent chemotherapy
            - '77301' # Radiation therapy planning (curative)
            days: 90
            description: No curative-intent treatment within past 90 days
      - prior_service_within_days:
          service_codes:
          - '99213' # Oncology evaluation
          - '99214'
          - '99215'
          days: 30
          description: Oncology evaluation within past 30 days
      - patient_age:
          min: 18
  logic:
    outcome: approved
    reason: ESA therapy approved for palliative cancer treatment with documented anemia
  metadata:
    source: UnitedHealth Medical Policy 2025.09
    effective_date: '2025-09-01'
    clinical_rationale: ESAs improve quality of life in palliative cancer patients with chemotherapy-induced anemia

- id: rule_oncology_platelet_growth_factor
  name: Platelet Growth Factor Therapy
  description: Prior authorization for thrombopoietin receptor agonists in cancer patients
  type: PRIOR_AUTH
  scope:
    service_types: ["MEDICAL"]
    place_of_service: ["11", "22"]
  conditions:
    all_of:
      - service_code:
          any_of:
          - J3490  # Unclassified drugs (eltrombopag, romiplostim)
          - '96372' # Subcutaneous injection
      - diagnosis_code:
          any_of:
          - C78.00  # Secondary malignant neoplasm
          - C80.1   # Malignant neoplasm, unspecified
          - Z51.11  # Encounter for antineoplastic chemotherapy
          - D69.59  # Other secondary thrombocytopenia
      - prior_service_within_days:
          service_codes:
          - '85025' # Platelet count <50,000/μL
          - '85027'
          days: 7
          description: Severe thrombocytopenia within past week
      - prior_service_within_days:
          service_codes:
          - '96413' # Chemotherapy-induced thrombocytopenia
          - '96415'
          days: 21
          description: Chemotherapy administration within past 3 weeks
      - any_of:
        - prior_service_within_days:
            service_codes:
            - '99221' # Hospitalization for bleeding
            - '99222'
            - '99223'
            days: 14
            description: Bleeding complications within past 2 weeks
        - all_of:
          - prior_service_within_days:
              service_codes:
              - '96413' # Chemotherapy delay due to thrombocytopenia
              days: 14
              description: Treatment delay due to low platelets within past 2 weeks
      - prior_service_within_days:
          service_codes:
          - '99213' # Oncology evaluation
          - '99214'
          - '99215'
          days: 14
          description: Oncology evaluation within past 2 weeks
      - none_of:
        - diagnosis_code:
            any_of:
            - D69.3  # Immune thrombocytopenic purpura (different indication)
            - C95.90 # Acute leukemia (different management)
  logic:
    outcome: approved
    reason: Platelet growth factor approved for chemotherapy-induced thrombocytopenia with bleeding risk
  metadata:
    source: UnitedHealth Medical Policy 2025.09
    effective_date: '2025-09-01'
    clinical_rationale: TPO receptor agonists reduce bleeding risk and treatment delays in cancer patients

- id: rule_oncology_stem_cell_mobilization
  name: Stem Cell Mobilization Growth Factors
  description: Prior authorization for growth factors used in stem cell mobilization
  type: PRIOR_AUTH
  scope:
    service_types: ["MEDICAL"]
    place_of_service: ["11", "22"]
  conditions:
    all_of:
      - service_code:
          any_of:
          - J1442  # Injection, filgrastim
          - J2502  # Injection, plerixafor
          - '96372' # Subcutaneous injection
      - diagnosis_code:
          any_of:
          - C90.00  # Multiple myeloma
          - C81.90  # Hodgkin lymphoma
          - C85.90  # Non-Hodgkin lymphoma
          - C95.90  # Leukemia
      - prior_service_within_days:
          service_codes:
          - '99213' # Hematology-oncology consultation
          - '99214'
          - '99215'
          days: 30
          description: Hematology-oncology evaluation within past 30 days
      - any_of:
        - all_of:
          - diagnosis_code:
              any_of:
              - C90.00 # Multiple myeloma
          - prior_service_within_days:
              service_codes:
              - '96413' # Induction chemotherapy completed
              days: 90
              description: Induction chemotherapy within past 90 days
        - all_of:
          - diagnosis_code:
              any_of:
              - C81.90 # Lymphoma
              - C85.90
          - prior_service_within_days:
              service_codes:
              - '96413' # Salvage chemotherapy
              days: 60
              description: Salvage chemotherapy within past 60 days
      - prior_service_within_days:
          service_codes:
          - '85025' # Adequate blood counts for mobilization
          days: 7
          description: Blood count assessment within past week
      - prior_service_within_days:
          service_codes:
          - '38240' # Bone marrow transplant evaluation
          - '38241'
          days: 180
          description: Transplant evaluation within past 6 months
      - none_of:
        - diagnosis_code:
            any_of:
            - C78.00 # Solid tumor metastases (not transplant eligible)
        - patient_age:
            min: 70
  logic:
    outcome: approved
    reason: Stem cell mobilization approved for transplant-eligible hematologic malignancy
  metadata:
    source: UnitedHealth Medical Policy 2025.09
    effective_date: '2025-09-01'
    clinical_rationale: Growth factors facilitate adequate stem cell collection for autologous transplantation

- id: rule_oncology_bone_marrow_stimulation
  name: Bone Marrow Stimulation Post-Chemotherapy
  description: Prior authorization for growth factors supporting bone marrow recovery
  type: PRIOR_AUTH
  scope:
    service_types: ["MEDICAL"]
    place_of_service: ["11", "22", "19"]
  conditions:
    all_of:
      - service_code:
          any_of:
          - J1442  # Injection, filgrastim
          - J1447  # Injection, tbo-filgrastim
          - J0881  # Injection, darbepoetin alfa
          - J0885  # Injection, epoetin alfa
          - '96372' # Subcutaneous injection
      - diagnosis_code:
          any_of:
          - C78.00  # Secondary malignant neoplasm
          - C80.1   # Malignant neoplasm, unspecified
          - Z51.11  # Encounter for antineoplastic chemotherapy
          - D61.1   # Drug-induced aplastic anemia
      - prior_service_within_days:
          service_codes:
          - '96413' # High-dose chemotherapy
          - '96415'
          days: 14
          description: High-dose chemotherapy within past 2 weeks
      - prior_service_within_days:
          service_codes:
          - '85025' # Severe cytopenias
          - '85027'
          days: 7
          description: Severe bone marrow suppression within past week
      - any_of:
        - all_of:
          - prior_service_within_days:
              service_codes:
              - '85025' # ANC <500 cells/μL
              days: 3
              description: Severe neutropenia within past 3 days
        - all_of:
          - prior_service_within_days:
              service_codes:
              - '85025' # Hemoglobin <8 g/dL
              days: 7
              description: Severe anemia within past week
        - all_of:
          - prior_service_within_days:
              service_codes:
              - '85025' # Platelet count <20,000/μL
              days: 3
              description: Severe thrombocytopenia within past 3 days
      - prior_service_within_days:
          service_codes:
          - '99213' # Oncology evaluation
          - '99214'
          - '99215'
          days: 7
          description: Oncology evaluation within past week
      - none_of:
        - diagnosis_code:
            any_of:
            - C95.90 # Acute leukemia (specialized protocols)
  logic:
    outcome: approved
    reason: Growth factor support approved for severe chemotherapy-induced bone marrow suppression
  metadata:
    source: UnitedHealth Medical Policy 2025.09
    effective_date: '2025-09-01'
    clinical_rationale: Growth factors accelerate bone marrow recovery after intensive chemotherapy
